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In this issue of the SAMJ, Lessells et al.1 highlight the unacceptably 
high mortality due to HIV-associated cryptococcal meningitis (CM) 
in routine clinical practice in South Africa. CM is now the most 
common cause of adult meningitis in much of central and southern 
Africa, accounting for 63% of all microbiologically confirmed cases 
in the largest published series.2 There are an estimated 720 000 
cases annually in sub-Saharan Africa, leading to 504 000 deaths;3 
expanding access to antiretroviral therapy (ART) has not yet led to a 
decline in these numbers.4
In research settings in South Africa, utilising optimal amphotericin 
B-based treatments, acute mortality of CM is between 24 and 37%.5,6 
Lessells et al. suggest that, in routine care settings, mortality rates 
are higher.1 From their study conducted at Hlabisa Hospital in rural 
Kwazulu-Natal, they report 41% in-hospital mortality (all of which 
deaths occurred within 30 days of admission), which is in keeping 
with data from Johannesburg, where only 33% of CM patients were 
known to be alive and under follow-up at 12 weeks (Govender N, 
unpublished). Of even greater concern is their finding that only 11% 
of CM patients were alive and taking ART at 2 years. Although high 
early mortality rates are reported in African ART programmes, data 
from research settings in Cape Town show that, provided patients 
survive the acute illness, long-term survival of CM patients can be 
good once they have been established on ART.6
The excessive CM mortality in routine care compared with 
research settings is probably owing in part to patients’ difficulties 
accessing overloaded health care services. This issue almost certainly 
leads to delays in diagnosis when patients develop CM symptoms, 
resulting in advanced disease at presentation – a factor consistently 
identified as a risk for mortality. A further contributor is the lack 
of availability of amphotericin B (the optimal initial treatment for 
CM) in many hospitals. Outcomes with the alternative, fluconazole 
monotherapy as initial CM treatment, are poor.7 Lessells et al. report 
that only 35% of patients in their cohort received any amphotericin 
B, and only 8% received what is considered the optimal 2-week 
course. Unfortunately, this situation appears to be the norm in 
South Africa, where surveillance data suggest that less than half of 
patients are receiving optimal initial treatment for CM (even when 
optimal therapy is defined as a minimum of 1 week of amphotericin 
or fluconazole 800 mg daily).8 An additional critical aspect of the 
management of CM is correcting elevated CSF pressure (which is 
present in approximately 75% of CM cases at presentation9) with 
serial lumbar punctures. Guidance for therapeutic lumbar punctures 
is laid out in the Southern African HIV Clinicians Society CM 
treatment guidelines,10 and requires only basic equipment. But 
Lessells et al. demonstrate that this simple and important aspect of 
management is rarely carried out, which corroborates our anecdotal 
experience.
As Lessells and colleagues highlight, even given these inadequacies 
in initial treatment, the primary factor accounting for the exceptionally 
poor long-term outcomes was the loss of almost 50% of patients to 
follow-up on discharge from hospital. Only 20% of patients collected 
fluconazole secondary prophylaxis, and the majority did not initiate 
ART. The poor linkage from hospitals to outpatient services – 
and particularly linkage into ART care – is a major problem in 
South Africa, with many patients lost after inpatient treatment of 
opportunistic infections such as tuberculosis and CM. This clearly 
has serious implications, both in terms of short-term outcomes, 
with high rates of relapse of CM in patients not receiving adequate 
secondary fluconazole prophylaxis,11,12 and also preventing many 
lives being saved by timely initiation of ART.13 Patients with CM 
and other opportunistic infections involving the CNS represent a 
particularly vulnerable group in this regard. CNS disease is associated 
with high mortality and loss to follow-up from ART programmes, 
which is thought to result from impaired insight, cognition, mobility 
or volition.14 Thirty-four per cent of patients in the Lessells study 
had a depressed level of consciousness at the time of admission and, 
even though this may improve during CM treatment, many patients 
still have impaired cognition during their hospital stay. This impairs 
patients’ ability to comprehend counselling regarding the need for 
ongoing fluconazole, ART and outpatient follow-up. In addition, 
our experience suggests that insufficient time is spent counselling 
patients in this regard in their own language during an admission 
for CM.
What needs to be done? The good news is that, despite the 
poor outcomes described in the Kwazulu-Natal cohort, a series of 
straightforward steps could markedly improve outcomes, even with 
the currently available treatment options. Clinicians need to have 
a low threshold for suspecting CM, and all known or suspected 
HIV-infected patients with a new headache should have a diagnostic 
lumbar puncture. Amphotericin B should be made available to all 
clinicians treating such patients, and these clinicians should be 
educated about the importance of its role in initial therapy, and 
about the steps needed to monitor for and prevent its adverse effects. 
Manometers should be available, and clinicians must routinely 
measure CSF opening pressure in CM patients and manage it 
according to established guidelines. Importantly, in addition to 
improving inpatient treatment, subsequent linkage into outpatient 
ART services must be strengthened. This requires both a streamlining 
of the referral process with improved communication between 
inpatient and primary care providers, and specific counselling 
for patients, emphasising the importance of ongoing fluconazole 
treatment, the need for ART, and details about where to attend for 
outpatient care. Involving relatives or friends as treatment supporters 
during the admission, who could assist with ensuring that such 
vulnerable patients get to their outpatient appointments, assist with 
adherence to ART and fluconazole, and bring patients for medical 
attention if they deteriorate, could make an important difference to 
outcomes. Health care services must recognise and make provision 
for the fact that patients who have had an acute opportunistic 
infection (particularly those that involve the CNS) are vulnerable and 
need special attention in order to get them onto ART and specifically 
support them through the first months of treatment. Additional 
input, both medically and socially, during this early treatment period 
would pay dividends in terms of long-term survival.
More work is needed to develop simple to use, point-of-care diagnostic 
tests for CM, to develop improved initial treatments and to define the 
optimal timing of ART initiation. There is also the exciting possibility 
that much CM-related morbidity and mortality could be prevented 
by routine cryptococcal antigen screening of asymptomatic patients 
entering ART programmes.15 But, as Lessells and colleagues clearly 
demonstrate, CM is exacting a high toll in South African patients now. 
We can and must do better with the tools we already have.
The Southern African HIV Clinicians Society Guidelines for the 
Prevention, Diagnosis and Management of Cryptococcal Meningitis 
are accessible online at: http://sahivsoc.org/index.php?option=com_
docman&task=cat_view&gid=18&dir=DESC&order=date&Itemid=67&
limit=5&limitstart=5
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